This protocol is judged by an institutional review board, an impartial group that assessments any clinical trials involving people. If a study entails a Program I drug, as soon as the board approves the protocol as ethical, the researchers have to submit an application for an investigational new drug (IND) variety within the FDA.Prospects noted ve